Announcements Trials
Browse Landscape

Status

Completed 4Unknown 1Recruiting 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 234Observational 6Expanded_access 1

Sponsor

Cancer Type

Plasma cell 6Genitourinary 2

Conditions

Multiple Myeloma 6Acute Kidney Injury 2Personal Satisfaction 1Patient Satisfaction 1Patient Preference 1

Interventions

Bortezomib 20Blood Specimen Collection 9Surveys and Questionnaires 8Lenalidomide 8Dexamethasone 8pomalidomide 6daratumumab 6Flow Cytometry 6Immunoenzyme Techniques 5Biopsy 5plerixafor 4idecabtagene vicleucel 4carfilzomib 4Standard of Care 4Polymerase Chain Reaction 4Amplified Fragment Length Polymorphism Analysis 4Specimen Handling 3Psychiatric Rehabilitation 3Patient Reported Outcome Measures 3Microarray Analysis 3Melphalan 3Magnetic Resonance Spectroscopy 3Interviews as Topic 3Drug Therapy 3Data Collection 3Cytogenetic Analysis 3Chromatin Immunoprecipitation Sequencing 3talquetamab 2selinexor 2belantamab mafodotin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Observational × daratumumab × Plasma cell × Clear all
NCT06549634 2026-02-27

Biomarkers of AKI in Patients Receiving Daratumumab

Brigham and Women's Hospital

Completed
20 enrolled
GenitourinaryPlasma cell

Multiple Myeloma, Acute Kidney Injury

NCT06483139 2025-11-19

Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy

Brigham and Women's Hospital

Recruiting
450 enrolled
GenitourinaryPlasma cell

Multiple Myeloma, Acute Kidney Injury

NCT05835726 2025-08-15

DILEMMA

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Completed
188 enrolled
Plasma cell

Multiple Myeloma

NCT05284591 2024-10-01

MYLENE

iOMEDICO AG

Completed
96 enrolled
Plasma cell

Multiple Myeloma, Personal Satisfaction, Patient Satisfaction, Patient Preference

NCT05306587 2024-04-03

Daratumumab Provided at Home Experience An Open, Single-center, Mixed-method Project.

Odense University Hospital

Completed
40 enrolled
Plasma cell

Multiple Myeloma

NCT05218603 2022-09-16

Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

PETHEMA Foundation

Unknown
100 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡